FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy

STOCKHOLM, Aug. 18, 2023 -- (Healthcare Sales & Marketing Network) -- Calliditas Therapeutics AB (Nasdaq: CALT), (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced that the U.S. Food and Drug Administration (FDA) has accepted the submissi... Biopharmaceuticals Calliditas Therapeutics, TARPEYO, budesonide
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news